Neoclease Wins Chiesi Global Rare Diseases “Golden Ticket” for Lab Space at BioLabs Boston

October 24, 2024

We’re thrilled to share exciting news – Neoclease has been awarded a Golden Ticket from Chiesi Global Rare Diseases, granting us one year of lab space at BioLabs in Boston!

This prestigious award represents more than just physical space. It’s a powerful vote of confidence in our vision to redefine gene editing through the synergy of synthetic biology and AI-driven enzyme design. With Chiesi’s support, we’re better positioned than ever to push the boundaries of precision medicine and deliver breakthrough therapies for patients with genetic disorders.

The Golden Ticket gives us access to world-class facilities, resources, and mentorship at BioLabs, an ecosystem designed for startups to scale innovative science. For Neoclease, this means an accelerated path to developing and validating our next-generation gene editors, empowering us to make precision gene therapies more effective, safer, and accessible globally.

At Neoclease, we believe healthcare innovation thrives on collaboration. This partnership with Chiesi Global Rare Diseases aligns our mission to create transformative solutions for rare disease communities and beyond.

We’re deeply grateful to Chiesi for this opportunity and inspired to continue our journey toward a healthier world. Together, we’re driving the future of genetic medicine.